Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and, now, more deeply than before, into inflammation, penning a major $1.7 billion deal ...

Jan 11 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat patients with inflammatory ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Nurix Therapeutics (NRIX) leads in targeted protein modulation with its DELigase platform, developing BTK degraders like ...

In “Open Socrates,” the scholar Agnes Callard argues that the ancient Greek philosopher offers a blueprint for an ethical ...

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415 million. The agreement includes an upfront ...

In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed HIV with a single weekly oral dose, raising the hope of a new treatment option for patients.

In Nnedi Okorafor’s new novel, “Death of the Author,” a once-struggling writer grapples with power, privilege, agency and art ...

The Case for a Philosophical Life” is a look at how the ancient Greek philosopher's approach can be applied to the thorniest ...

The Inside Story of the Greatest Golf Ever Played,” explains how his new book gives deep insights into Tiger Woods' legendary ...